Monday - Friday
8:00 a.m. - 5:00 p.m.
Licensed under
Inderbir S. Gill, MD, is Chairman & Distinguished Professor, Catherine & Joseph Aresty Department of Urology; Executive Director, USC Institute of Urology; and the Shirley & Donald Skinner Chair in Urologic Cancer Surgery at the Keck School of Medicine, University of Southern California, Los Angeles. Prior to this, he was chairman & professor, department of urology at the Cleveland Clinic, Cleveland, OH, where he was on faculty for 12 years (1997-2009).
During his 14 years in Los Angeles since 2009, USC Urology has grown in scientific stature, clinical volumes, financial productivity & philanthropy. As a result, USC Urology has progressed in U.S. News & World Report national rankings from being outside the ‘Top 50’ until 2011, to #4 in 2019, and has ranked in the ‘Top 10’ for 5 years in a row (2018-2022). In NIH Blue Ridge national rankings, USC Urology elevated from #26 in 2017 to #2 nationally (2022, 2023).
Dr Gill has published ~980 scientific papers with ~50 400 citations. His H-index is 119, amongst the highest in the entire field of urology. He is principal investigator of a funded R-01 grant from NCI, and co-PI on other NIH grants. He is published in prestigious journals including N. Engl. J. Med., Nature, Nature Medicine, Lancet, Lancet Oncology, JAMA Surgery, etc. He has edited/co-edited 10 textbooks and has been on the editorial boards of 9 urologic journals. Dr Gill has been invited for over 450 visiting professorships, invited lectures and live surgery demonstrations world-wide. He is elected to the prestigious American Association of Genito-Urinary Surgeons (2003) and the Clinical Society of AAGUS (2009).
His various honors include: the Dr. B. C. Roy National Award for Eminent Medical Person awarded by the President of India (2005); St. Paul’s Medal by the British Urological Association (2006); honorary Fellow of the Royal College of Surgeons of England; President, 24th World Congress of Endourology & SWL (2006); USC Presidential Medallion (2013); listed in Thomson Reuters “The World’s Most Influential Scientific Minds” (2014); AUA Ramon Guiteras Lecturer (2015); AUA Chair, Global Initiatives (2015-2017); AAGUS Membership Committee (2021-2025); AUA Presidential Citation for Outstanding Contributions to Robotic Urologic Oncologic Surgery (2022); and SIU Distinguished Career Award by the Societe’ Internationale D' Urologie (2022); and the Spence Medal from the AAGUS (2024), one of the highest honors in the field.
His primary academic focus is advanced robotic urologic oncologic surgery for cancers of the kidney, bladder and prostate. His aggregate team has amongst the world’s pre-eminent robotic/laparoscopic case volumes for urologic oncologic surgery, with over 15,000+ cases in the USA. More recently, his interest has expanded to focal targeted therapy for prostate cancer. He and his team are now exploring artificial intelligence (AI) applications in urology. In 2021, under his leadership, USC Urology established the first, foundation-funded, dedicated Urology AI Center in a urology department in the nation.
On May 4, 2025, Dr Gill and his team performed the world’s first-in-human bladder transplant. https://www.nytimes.com/2025/05/18/health/bladder-transplant-human.html.
To date, Dr Gill has had the privilege to train over 120 urology residents and over 140 post-graduate fellows in robotic & minimally invasive urologic oncologic surgery. His fellows and faculty members are also making innovative contributions to the field, and notably, at this writing, 14 of them are current Chairs of highly prestigious urology departments nationally and internationally.
Benefits among health plans and employers vary. Please contact your health plan to verify benefits and network providers for specific products. It is important to note that not all of our providers participate in all of a health plan's products or networks.
